Xcelerate (XCRT) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue was $531,921, down from $558,000 YoY; net loss narrowed to $82,856 from $244,251. Nine-month revenue and net loss were $1,713,853 and $466,277, respectively.

• September 30 cash was $202,554 against $3,475,687 of liabilities and a $1,675,401 stockholders’ deficit; the statements cite substantial doubt about continued operations.

Financial highlights

• Q3 gross margin dollars were $217,147 versus $206,543 YoY; nine-month gross margin dollars were $591,567 versus $518,270.

• Q3 operating loss was $56,731 versus $244,251 YoY; nine-month operating loss was $351,050 versus $744,838.

• Nine-month net loss attributable to common shareholders was $335,186 versus $545,454 in 2024; basic and diluted loss per share was $0.00 in both periods, rounded as presented.

• Total assets were $1,800,285 at September 30, 2025, versus $1,680,044 at December 31, 2024; total liabilities rose to $3,475,687 from $2,889,168.

• Cash increased to $202,554 from $123,548 at year-end 2024; nine-month net increase in cash was $79,006.

Outlook and guidance

• Resources are expected to focus on consumer health and beauty products and virtual health services; licensing medical-equipment rights may be pursued when monetization opportunities arise.

• Existing operating cash flow is not expected to fund anticipated operations; additional financing is needed until operations become profitable.